FINWIRES · TerminalLIVE
FINWIRES

Vermilion公司公布第一季度产量和销量均有所增长；维持2026年展望不变。

By

-- Vermilion Energy (VET) 周三公布了第一季度财报。该公司表示，截至3月31日的第一季度，其石油总产量为每日125,618桶油当量，高于去年同期的103,115桶油当量/日。 Vermilion称，天然气产量从去年同期的每日3.6936亿立方英尺增至每日5.3929亿立方英尺，天然气凝析液产量从每日9,167桶增至每日12,044桶。 该公司表示，原油和凝析油产量从去年同期的每日32,386桶降至每日23,692桶。 Vermilion补充道，第一季度其加拿大业务的平均产量为每日99,746桶油当量，较上一季度增长10%；国际业务总产量为每日25,872桶油当量。 Vermilion公司表示，其第一季度综合销量为126,867桶油当量/日，高于去年同期的102,427桶油当量/日。 Vermilion公司称，该季度原油和凝析油销量下降至24,941桶/日，而去年同期为31,698桶/日；天然气液体销量则从9,167桶/日增至12,044桶/日。 该公司补充道，天然气销量从去年同期的3.6936亿立方英尺/日增至5.3929亿立方英尺/日。 据该公司称，Vermilion预计第二季度平均日产量为12.3万桶油当量至12.5万桶油当量，并维持全年日产量11.8万桶油当量至12.2万桶油当量的预期，勘探和开发支出为6亿加元（4.402亿美元）至6.3亿加元。

Price: $11.82, Change: $-1.81, Percent Change: -13.28%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL